FUSILEV J Code: J0641

Drug & Product Overview

HCPCS Descriptor Injection, levoleucovorin, not otherwise specified, 0.5 mg

HCPCS Added Date January 1, 2009

Manufacturer Multiple Manufacturers

Route of Administration Intravenous

Generic Status Multi-Source; Generic

Dosage Type Single-Dose

Dosage Form Injection, Powder, Lyophilized, For Solution | Injection, Solution | Not Available

About FUSILEV

Fusilev is a medication aligned to the HCPCS J Code: J0641 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by multiple companies.

According to CMS Drug Use Information: This medication is used to treat or prevent serious blood cell disorders (such as thrombocytopenia, neutropenia, anemia) caused by certain drugs (folic acid antagonists such as methotrexate, trimethoprim, pyrimethamine). Some brands may also be used with a certain cancer drug (5-fluorouracil) to treat patients with colon cancer.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. Showing 4 of 8 NDCs — log in for the full crosswalk.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
70436-0209-80	Levoleucovorin Calcium	Slate Run Pharmaceuticals	350	175 MG / 17.5 ML
71288-0104-10	Levoleucovorin Calcium	Meitheal Pharmaceuticals Inc.	100	50 MG
71288-0105-18	Levoleucovorin	Meitheal Pharmaceuticals Inc.	350	175 MG / 17.5 ML
72266-0120-01	Levoleucovorin Calcium	Fosun Pharma USA Inc.	350	175 MG / 17.5 ML
•••••-••••-•• Log in to view	FUSILEV
	FUSILEV
	FUSILEV

Login to view 4 more NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

FUSILEV Pricing & Reimbursement

J0641 Private Payer Reimbursement

$0.06 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

FUSILEV Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 14.92%

Avg. Days to File 10.3days

Avg. Days to Pay 24.6days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J0641 claims analytics on FocalPoint →

FUSILEV CPT Administration Codes

CPT Code	Description
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96413 Login for More	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug Login for More
96415 Login for More	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) Login for More

JW / JZ modifiers apply

CMS has identified Fusilev (J0641) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

FUSILEV Medically Unlikely Edits (MUE)

The most billing units of J0641 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.5 mg.

Practitioner Office & Hospital Outpatient

1,200 units / day

= 600 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

FUSILEV Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Advanced metastatic colorectal cancer Impaired methotrexate elimination / inadvertent folic acid antagonist overdosage Metastatic colorectal cancer Osteosarcoma Overdosage of folic acid antagonists or impaired methotrexate elimination

Drug Class

Folate Analog [EPC]Folic Acid [CS]

Frequently Asked Questions

Is there an available Fusilev billing and coding guide?

We have not yet identified a manufacturer source of Fusilev billing and coding information.

Are there any available Fusilev patient assistance programs?

Our team did not identify a source for Fusilev patient assistance information. Please reach out to our team if you feel that this is a mistake.

Where can I find Fusilev prescribing information?

FUSILEV prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date. Visit Here →

Where can I find Fusilev side effect information?

Our team has not yet identified a source of side effects information for FUSILEV. Please check back in a few weeks.

Does billing FUSILEV require JZ/JW wastage modifiers?

CMS has identified FUSILEV(J0641) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.